Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

Summary

Aim of this phase 2 study is to explore the safety and efficacy of thoracic re-irradiation +/- SBRT to oligometastases (\<3) followed after an interval of 2 weeks by durvalumab and ceralasertib for patients with thoracic relapses +/- oligometastases after PACIFIC or PACIFIC-like (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab) regimens.

Timeline

Start

2025-08-07

Primary completion

2028-06

Completion

2029-01

Publications

• Filippi AR, Rulli E, Signorelli D, Willmann J, Durham A, De Simone I, Santoni A, Galli F, Carlucci L, Torri V, Lo Russo G, Addeo A, Guckenberger M. Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen. Clin Lung Cancer. 2025 Dec;26(8):e633-e638. doi: 10.1016/j.cllc.2025.07.006. Epub 2025 Jul 12.

Drugs

Indications